Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) Research & Development (2016 - 2025)

Historic Research & Development for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $167000.0.

  • Utah Medical Products' Research & Development fell 290.7% to $167000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $577000.0, marking a year-over-year decrease of 3122.77%. This contributed to the annual value of $813000.0 for FY2024, which is 4517.86% up from last year.
  • According to the latest figures from Q3 2025, Utah Medical Products' Research & Development is $167000.0, which was down 290.7% from $135000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Research & Development registered a high of $266000.0 during Q1 2024, and its lowest value of $112000.0 during Q3 2022.
  • Over the past 5 years, Utah Medical Products' median Research & Development value was $135000.0 (recorded in 2022), while the average stood at $150000.0.
  • Per our database at Business Quant, Utah Medical Products' Research & Development skyrocketed by 9172.93% in 2024 and then tumbled by 4705.88% in 2025.
  • Over the past 5 years, Utah Medical Products' Research & Development (Quarter) stood at $141000.0 in 2021, then fell by 12.77% to $123000.0 in 2022, then rose by 18.7% to $146000.0 in 2023, then fell by 17.12% to $121000.0 in 2024, then surged by 38.02% to $167000.0 in 2025.
  • Its Research & Development was $167000.0 in Q3 2025, compared to $135000.0 in Q2 2025 and $154000.0 in Q1 2025.